- Home
- FCAP vs MOLN Comparison
FCAP vs MOLN Comparison
Compare FCAP & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCAP
- MOLN
- Stock Information
- Founded
- FCAP 1891
- MOLN 2004
- Country
- FCAP United States
- MOLN Switzerland
- Employees
- FCAP N/A
- MOLN N/A
- Industry
- FCAP Savings Institutions
- MOLN
- Sector
- FCAP Finance
- MOLN
- Exchange
- FCAP Nasdaq
- MOLN Nasdaq
- Market Cap
- FCAP 125.9M
- MOLN 142.5M
- IPO Year
- FCAP 1999
- MOLN 2021
- Fundamental
- Price
- FCAP $44.01
- MOLN $4.50
- Analyst Decision
- FCAP
- MOLN Hold
- Analyst Count
- FCAP 0
- MOLN 1
- Target Price
- FCAP N/A
- MOLN $4.00
- AVG Volume (30 Days)
- FCAP 3.6K
- MOLN 6.5K
- Earning Date
- FCAP 10-24-2025
- MOLN 10-30-2025
- Dividend Yield
- FCAP 2.79%
- MOLN N/A
- EPS Growth
- FCAP 25.19
- MOLN N/A
- EPS
- FCAP 4.41
- MOLN N/A
- Revenue
- FCAP $47,323,000.00
- MOLN N/A
- Revenue This Year
- FCAP N/A
- MOLN N/A
- Revenue Next Year
- FCAP N/A
- MOLN $1,000.00
- P/E Ratio
- FCAP $9.69
- MOLN N/A
- Revenue Growth
- FCAP 15.22
- MOLN N/A
- 52 Week Low
- FCAP $28.50
- MOLN $3.36
- 52 Week High
- FCAP $53.85
- MOLN $6.24
- Technical
- Relative Strength Index (RSI)
- FCAP 57.27
- MOLN 67.27
- Support Level
- FCAP $42.71
- MOLN $3.72
- Resistance Level
- FCAP $44.00
- MOLN $4.72
- Average True Range (ATR)
- FCAP 0.80
- MOLN 0.18
- MACD
- FCAP 0.20
- MOLN 0.07
- Stochastic Oscillator
- FCAP 100.00
- MOLN 81.51
About FCAP First Capital Inc.
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.